Floatz logo

Enasidenib

Angioimmunoblastic T-cell Lymphoma

CelgeneSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Angioimmunoblastic T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
Shandong Provincial Hospital
Phase 4BBB
DEXAMETHASONE
Ou Bai, MD/PHD
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 4BB
ETOPOSIDE
Eric Jacobsen, MD
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Enasidenib is also rated in:

IDH2 Gene MutationDormant
BB
Indicative ·
64 / 100
View asset →
Isocitrate DehydrogenaseDormant
BB
Indicative ·
64 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →